# Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

> **NCT00138632** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 50 (actual)

## Conditions studied

- Wet Age-Related Macular Degeneration

## Interventions

- **DRUG:** PTK787
- **DRUG:** PTK787
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00138632
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2007-11
- **Final completion:** —
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2008-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00138632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00138632, "Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00138632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*